Gene Therapy Market Size, Share, Trends, Industry Analysis Report : By Therapeutic Area, Vector Type (Viral, Non-Viral), Approach, Route of Administration, and Region

Description

List of Tables

The gene therapy market size is expected to reach USD 29.01 billion by 2035, according to a new study by Polaris Market Research. The report "Gene Therapy Market Size, Share, Trends, Industry Analysis Report: By Therapeutic Area, Vector Type (Viral, Non-Viral), Approach, Route of Administration, and Region - Market Forecast 2026-2035" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Gene therapy involves modifying or replacing unhealthy genes within a patient's cells to treat or prevent disease. Rapid advancements in genetic engineering and an increasing understanding of molecular biology are propelling gene therapy from experimental stages to real-world clinical applications. Researchers and biopharmaceutical companies invest heavily in developing safe and effective therapies. Also, regulatory bodies streamline approval processes, which accelerates gene therapy industry expansion.

The demand for gene therapy has surged due to the increasing prevalence of genetic disorders, such as Duchenne muscular dystrophy (DMD), sickle cell disease, hemophilia, and cystic fibrosis. Unlike traditional treatment methods that primarily focus on symptom management, gene therapy targets the underlying genetic cause of these diseases. This targeted approach enhances treatment efficacy. It also offers the potential for long-term or even permanent relief. Significant breakthroughs in gene-editing technologies, such as CRISPR-Cas9 and zinc finger nucleases (ZFNs), have enabled precise and efficient gene modifications.

The rising number of regulatory approvals for gene-based treatments drives the gene therapy market growth. Government agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) recognized the transformative potential of these therapies. They are expediting the approval process for promising candidates. Therapies such as Zolgensma for spinal muscular atrophy (SMA) and Luxturna for inherited retinal disease have demonstrated remarkable clinical success. This approach is paving the way for broader adoption of gene-based therapies or treatments.

Gene Therapy Market Report Highlights

Based on therapeutic area, the oncological disorders segment led the gene therapy market share in 2025. The prevalence of significant physical and psychological impacts of the disease and its treatment contributed to the dominance.

By vector type, the viral segment dominated the revenue share in 2025. The leading position is attributed to its effective and efficient delivering genes to the targeted cells for various cancers, monogenic and infectious diseases.

North America held the largest revenue share in 2025. The regional industry growth is driven by robust research infrastructure and advanced healthcare system. Also, significant funding for clinical trials and a supportive regulatory framework, particularly from the FDA, allows for rapid development and approval of new gene therapies. This factor also boosts the North America gene therapy industry growth.

Abeona Therapeutic, Novartis AG, Spark Therapeutics LLC, Gilead Sciences Inc., Bristol Myers Squibb, Adverum Biotechnologies, Alnylam Pharmaceuticals, American Gene Technologies, Applied Genetic Technologies Corporation, Biogen, and Ultragenyx are among the global market players.

Where is the Gene Therapy Market Headed?

According to our research on gene therapy industry, the market is expected to grow in the coming years due to rising approvals for therapies and technological evolution. Also, venture capital firms and large pharma companies are increasingly investing in vector technologies and delivery mechanisms. Such strategies will boost innovation and capacity expansion in the coming years.

What Does Gene Therapy Report Reveal?

What is the market size and CAGR for the market during 2026-2035?

What are the market drivers, trends, opportunities, and challenges?

Who are the key industry players? What is their relative position in terms of competitive positioning?

What are the leading candidates and technologies?

How do different treatment approaches, such as gene augmentation, oncolytic viral therapy, and immunotherapy, influence the market landscape?

How does the industry differ in terms of therapeutic area, vector type, approach, route of administration, and geography? Which is the leading vector type?

Among North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, which region shows growth potential?

Polaris Market Research has segmented the market report on the basis of therapeutic area, vector type, approach, route of administration, and region:

By Type Therapeutic Area Outlook (Revenue, USD Billion, 2022-2035)

Autoimmune Disorders

Cardiovascular Diseases

Dermatological Disorders

Hematological Disorders

Metabolic Disorders

Muscle-Related Diseases

Oncological Disorders

Others

By Vector Type Outlook (Revenue, USD Billion, 2022-2035)

Viral

Non-Viral

By Approach Outlook (Revenue, USD Billion, 2022-2035)

Gene Augmentation

Oncolytic Viral Therapy

Immunotherapy

Other Approaches

By Route of Administration Outlook (Revenue, USD Billion, 2022-2035)

Intraarticular

Intracerebellar

Intradermal

Intramuscular

Intratumoral

Intravenous

Intravesical

Intravitreal

Subretinal

Others

By Regional Outlook (Revenue, USD Billion, 2022-2035)

North America

U.S.

Canada

Europe

Germany

France

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Product Code: PM1084

Chapter 1. Introduction

1.1 Report Description
- 1.1.1 Objectives of the Study
- 1.1.2 Market Scope
- 1.1.3 Assumptions
1.2 Stakeholders

Chapter 2. Executive Summary

Chapter 3. Research Methodology

3.1 Overview
- 3.1.1 Data Mining
3.2 Data Sources
- 3.2.1 Primary Sources
- 3.2.2 Secondary Sources

Chapter 4. Gene Therapy Market Insights

4.1 Gene Therapy - Industry snapshot
4.1 Gene Therapy Market Dynamics
- 4.1.1 Drivers and Opportunities
  - 4.1.1.1 Rising Approval and Investments in Gene Therapy Development
  - 4.1.1.2 Growing burden of genetic and rare diseases
  - 4.1.1.3 Regulatory momentum & increasing approvals
- 4.1.2 Restraints and Challenges
  - 4.1.2.1 High cost per therapy and affordability barriers
  - 4.1.2.2 Manufacturing complexity and supply chain constraints
  - 4.1.2.3 Lack of Healthcare Infrastructure
4.2 Gene Therapy Market - Porter's Five Forces
- 4.2.1 Bargaining Power of Suppliers (High)
- 4.2.2 Threats of New Entrants: (Low)
- 4.2.3 Bargaining Power of Buyers (Moderate)
- 4.2.4 Threat of Substitute (Low)
- 4.2.5 Rivalry among existing firms (High)
4.3 Gene Therapy Market - PEST Analysis
4.4 Covid-19 Impact Analysis & Industry Trends

Chapter 5. Gene Therapy Market Assessment by Therapeutic Area

5.1 Introduction
5.2 Autoimmune Disorders
5.3 Cardiovascular Diseases
5.4 Dermatological Disorders
5.5 Hematological Disorders
5.6 Metabolic Disorders
5.7 Muscle-related Diseases
5.8 Oncological Disorders
5.9 Other Therapeutic Areas

Chapter 6. Gene Therapy Market Assessment by Vector Type

6.1 Introduction
6.2 Viral
- 6.2.1 Retroviral vectors
  - 6.2.1.1 Gamma-retroviral vectors
  - 6.2.1.2 Lentiviral vectors
- 6.2.2 Adeno-associated virus vectors
- 6.2.3 Other viral vectors
6.3 Non-Viral
- 6.3.1 Oligonucleotides
- 6.3.2 Other non-viral vectors

Chapter 7. Gene Therapy Market Assessment by Approach

7.1 Introduction
7.2 Gene Augmentation
7.1 Oncolytic Viral Therapy
7.2 Immunotherapy
7.3 Other Approaches

Chapter 8. Gene Therapy Market Assessment by Route of Administration

8.1 Introduction
8.2 Intraarticular
8.3 Intracerebellar
8.4 Intradermal
8.5 Intramuscular
8.6 Intratumoral
8.7 Intravenous
8.8 Intravesical
8.9 Intravitreal
8.10 Subretinal
8.11 Others

Chapter 9. Gene Therapy Market Assessment by Region

9.1 Introduction
9.2 Gene Therapy Market - North America
- 9.2.1 Gene Therapy Market - U.S.
- 9.2.2 Gene Therapy Market - Canada
9.3 Gene Therapy Market - Europe
- 9.3.1 Gene Therapy Market - Germany
- 9.3.2 Gene Therapy Market - UK
- 9.3.3 Gene Therapy Market - France
- 9.3.4 Gene Therapy Market - Italy
- 9.3.5 Gene Therapy Market - Spain
- 9.3.6 Gene Therapy Market - Netherlands
- 9.3.7 Gene Therapy Market - Austria
9.4 Gene Therapy Market - Asia Pacific
- 9.4.1 Gene Therapy Market - China
- 9.4.2 Gene Therapy Market - India
- 9.4.3 Gene Therapy Market - Japan
- 9.4.4 Gene Therapy Market - South Korea
9.5 Gene Therapy Market - Latin America
- 9.5.1 Gene Therapy Market - Brazil
- 9.5.2 Gene Therapy Market - Mexico
9.6 Gene Therapy Market - Middle East & Africa
- 9.6.1 Gene Therapy Market - Saudi Arabia
- 9.6.2 Gene Therapy Market - UAE

Chapter 10. Competitive Landscape

10.1 Key Market Players: Categorization
10.2 Strategy Framework
10.3 Vendor Landscape
10.4 Strategies Categorization
- 10.4.1 Partnerships/Collaborations/Agreements
- 10.4.2 Expansions/Mergers/Acquisitions
- 10.4.3 Product Development/New Launch

Chapter 11. Company Profiles

11.1 Sangamo Biosciences
- 11.1.1 Business Overview
- 11.1.2 Financial Snapshot
- 11.1.3 Products and Services
- 11.1.4 Recent Developments
11.2 Voyager Therapeutics
- 11.2.1 Business Overview
- 11.2.2 Financial Snapshot
- 11.2.3 Products and Services
- 11.2.4 Recent Developments
11.3 Ultragenyx
- 11.3.1 Business Overview
- 11.3.2 Financial Snapshot
- 11.3.3 Products and Services
- 11.3.4 Recent Developments
11.4 GlaxoSmithKline
- 11.4.1 Business Overview
- 11.4.2 Financial Snapshot
- 11.4.3 Products and Services
- 11.4.4 Recent Developments
11.5 Gilead Sciences Inc
- 11.5.1 Business Overview
- 11.5.2 Financial Snapshot
- 11.5.3 Products and Services
- 11.5.4 Recent Developments
11.6 Bristol Myers Squibb
- 11.6.1 Business Overview
- 11.6.2 Financial Snapshot
- 11.6.3 Products and Services
- 11.6.4 Recent Developments
11.7 Novartis AG
- 11.7.1 Business Overview
- 11.7.2 Financial Snapshot
- 11.7.3 Products and Services
- 11.7.4 Recent Developments
11.8 Spark Therapeutics LLC
- 11.8.1 Business Overview
- 11.8.2 Products and Services
- 11.8.3 Recent Developments
11.9 Bluebird Bio
- 11.9.1 Business Overview
- 11.9.2 Recent Developments
- 11.9.3 Products and Services
- 11.9.4 Recent Developments

Product Code: PM1084

List of Tables

Table 1 Global Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 1 Global Gene Therapy Market, by Autoimmune Disorders, 2022-2035 (USD Million)
Table 2 Global Gene Therapy Market, by Cardiovascular Diseases, 2022-2035 (USD Million)
Table 3 Global Gene Therapy Market, by Dermatological Disorders, 2022-2035 (USD Million)
Table 4 Global Gene Therapy Market, by Hematological Disorders, 2022-2035 (USD Million)
Table 5 Global Gene Therapy Market, by Metabolic Disorders, 2022-2035 (USD Million)
Table 6 Global Gene Therapy Market, by Muscle-related Diseases, 2022-2035 (USD Million)
Table 7 Global Gene Therapy Market, by Oncological Disorders, 2022-2035 (USD Million)
Table 8 Global Gene Therapy Market, by Other Therapeutic Areas, 2022-2035 (USD Million)
Table 9 Global Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 10 Global Gene Therapy Market, by Viral, 2022-2035 (USD Million)
Table 11 Global Gene Therapy Market, by Retroviral vectors, 2022-2035 (USD Million)
Table 12 Global Gene Therapy Market, by Gamma-retroviral vectors, 2022-2035 (USD Million)
Table 13 Global Gene Therapy Market, by Lentiviral vectors, 2022-2035 (USD Million)
Table 14 Global Gene Therapy Market, by Adeno-associated virus vectors, 2022-2035 (USD Million)
Table 15 Global Gene Therapy Market, by Other viral vectors, 2022-2035 (USD Million)
Table 16 Global Gene Therapy Market, by Non-Viral, 2022-2035 (USD Million)
Table 17 Global Gene Therapy Market, by Oligonucleotides, 2022-2035 (USD Million)
Table 18 Global Gene Therapy Market, by Other non-viral vectors, 2022-2035 (USD Million)
Table 19 Global Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 20 Global Gene Therapy Market, by Gene Augmentation, 2022-2035 (USD Million)
Table 21 Global Gene Therapy Market, by Oncolytic Viral Therapy, 2022-2035 (USD Million)
Table 22 Global Gene Therapy Market, by Immunotherapy, 2022-2035 (USD Million)
Table 23 Global Gene Therapy Market, by Other Approaches, 2022-2035 (USD Million)
Table 24 Global Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 25 Global Gene Therapy Market, by Intraarticular, 2022-2035 (USD Million)
Table 26 Global Gene Therapy Market, by Intracerebellar, 2022-2035 (USD Million)
Table 27 Global Gene Therapy Market, by Intradermal, 2022-2035 (USD Million)
Table 28 Global Gene Therapy Market, by Intramuscular, 2022-2035 (USD Million)
Table 29 Global Gene Therapy Market, by Intratumoral, 2022-2035 (USD Million)
Table 30 Global Gene Therapy Market, by Intravenous, 2022-2035 (USD Million)
Table 31 Global Gene Therapy Market, by Intravesical, 2022-2035 (USD Million)
Table 32 Global Gene Therapy Market, by Intravitreal, 2022-2035 (USD Million)
Table 33 Global Gene Therapy Market, by Subretinal, 2022-2035 (USD Million)
Table 34 Global Gene Therapy Market, by Others, 2022-2035 (USD Million)
Table 35 Gene Therapy Market Assessment, By Geography, 2022-2035 (USD Million)
Table 36 North America Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 37 North America Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 38 North America Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 39 North America Gene Therapy Market, By Retroviral Vector, 2022-2035 (USD Million)
Table 40 North America Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 41 North America Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 42 North America Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 43 U.S. Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 44 U.S. Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 45 U.S. Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 46 U.S. Gene Therapy Market, By Retroviral vectors, 2022-2035 (USD Million)
Table 47 U.S. Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 48 U.S. Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 49 U.S. Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 50 Canada Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 51 Canada Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 52 Canada Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 53 Canada Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 54 Canada Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 55 Canada Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 56 Canada Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 57 Europe Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 58 Europe Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 59 Europe Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 60 Europe Gene Therapy Market, By Retroviral vectors, 2022-2035 (USD Million)
Table 61 Europe Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 62 Europe Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 63 Europe Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 64 Germany Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 65 Germany Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 66 Germany Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 67 Germany Gene Therapy Market, By Retroviral Vector, 2022-2035 (USD Million)
Table 68 Germany Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 69 Germany Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 70 Germany Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 71 UK Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 72 UK Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 73 UK Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 74 UK Gene Therapy Market, By Retroviral vectors, 2022-2035 (USD Million)
Table 75 UK Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 76 UK Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 77 UK Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 78 France Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 79 France Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 80 France Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 81 France Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 82 France Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 83 France Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 84 France Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 85 Italy Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 86 Italy Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 87 Italy Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 88 Italy Gene Therapy Market, By Retroviral vectors, 2022-2035 (USD Million)
Table 89 Italy Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 90 Italy Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 91 Italy Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 92 Spain Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 93 Spain Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 94 Spain Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 95 Spain Gene Therapy Market, By Retroviral Vector, 2022-2035 (USD Million)
Table 96 Spain Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 97 Spain Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 98 Spain Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 99 Netherlands Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 100 Netherlands Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 101 Netherlands Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 102 Netherlands Gene Therapy Market, By Retroviral vectors, 2022-2035 (USD Million)
Table 103 Netherlands Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 104 Netherlands Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 105 Netherlands Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 106 Austria Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 107 Austria Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 108 Austria Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 109 Austria Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 110 Austria Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 111 Austria Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 112 Austria Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 113 Asia Pacific Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 114 Asia Pacific Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 115 Asia Pacific Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 116 Asia Pacific Gene Therapy Market, By Retroviral vectors, 2022-2035 (USD Million)
Table 117 Asia Pacific Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 118 Asia Pacific Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 119 Asia Pacific Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 120 China Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 121 China Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 122 China Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 123 China Gene Therapy Market, By Retroviral Vector, 2022-2035 (USD Million)
Table 124 China Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 125 China Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 126 China Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 127 India Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 128 India Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 129 India Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 130 India Gene Therapy Market, By Retroviral vectors, 2022-2035 (USD Million)
Table 131 India Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 132 India Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 133 India Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 134 Japan Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 135 Japan Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 136 Japan Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 137 Japan Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 138 Japan Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 139 Japan Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 140 Japan Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 141 South Korea Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 142 South Korea Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 143 South Korea Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 144 South Korea Gene Therapy Market, By Retroviral vectors, 2022-2035 (USD Million)
Table 145 South Korea Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 146 South Korea Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 147 South Korea Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 148 Latin America Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 149 Latin America Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 150 Latin America Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 151 Latin America Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 152 Latin America Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 153 Latin America Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 154 Latin America Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 155 Brazil Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 156 Brazil Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 157 Brazil Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 158 Brazil Gene Therapy Market, By Retroviral vectors, 2022-2035 (USD Million)
Table 159 Brazil Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 160 Brazil Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 161 Brazil Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 162 Mexico Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 163 Mexico Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 164 Mexico Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 165 Mexico Gene Therapy Market, By Retroviral Vector, 2022-2035 (USD Million)
Table 166 Mexico Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 167 Mexico Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 168 Mexico Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 169 Middle East & Africa Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 170 Middle East & Africa Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 171 Middle East & Africa Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 172 Middle East & Africa Gene Therapy Market, By Retroviral vectors, 2022-2035 (USD Million)
Table 173 Middle East & Africa Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 174 Middle East & Africa Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 175 Middle East & Africa Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 176 Saudi Arabia Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 177 Saudi Arabia Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 178 Saudi Arabia Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 179 Saudi Arabia Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 180 Saudi Arabia Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 181 Saudi Arabia Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 182 Saudi Arabia Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)
Table 183 UAE Gene Therapy Market, By Therapeutic Area, 2022-2035 (USD Million)
Table 184 UAE Gene Therapy Market, By Vector Type, 2022-2035 (USD Million)
Table 185 UAE Gene Therapy Market, By Viral Vector, 2022-2035 (USD Million)
Table 186 UAE Gene Therapy Market, By Retroviral vectors, 2022-2035 (USD Million)
Table 187 UAE Gene Therapy Market, By Non-viral vectors, 2022-2035 (USD Million)
Table 188 UAE Gene Therapy Market, By Approach, 2022-2035 (USD Million)
Table 189 UAE Gene Therapy Market, By Route of Administration, 2022-2035 (USD Million)

List of Figures

Figure 1. Executive Summary
Figure 2. Research Methodology: Top Down & Bottom-Up Approach
Figure 3. Market by Geography, 2022-2035 (USD Million)
Figure 6. Porter's Five Forces
Figure 7. PEST Analysis
Figure 8. Market by Therapeutic Area
Figure 9. Global Gene Therapy Market, By Therapeutic Area, 2025 & 2035 (USD Million)
Figure 10. Market by Vector Type
Figure 11. Global Gene Therapy Market, By Vector Type, 2025 & 2035 (USD Million)
Figure 12. Market by Approach
Figure 13. Global Gene Therapy Market, By Approach, 2025 & 2035 (USD Million)
Figure 14. Market by Route of Administration
Figure 15. Global Gene Therapy Market, By Route of Administration, 2025 & 2035 (USD Million)
Figure 16. Gene Therapy Market Assessment, By Geography, 2025 & 2035 (USD Million)

Gene Therapy Market Size, Share, Trends, Industry Analysis Report : By Therapeutic Area, Vector Type (Viral, Non-Viral), Approach, Route of Administration, and Region - Market Forecast 2026-2035

Description

Table of Contents

List of Tables

Gene Therapy Market Report Highlights

Table of Contents

Chapter 1. Introduction

Chapter 2. Executive Summary

Chapter 3. Research Methodology

Chapter 4. Gene Therapy Market Insights

Chapter 5. Gene Therapy Market Assessment by Therapeutic Area

Chapter 6. Gene Therapy Market Assessment by Vector Type

Chapter 7. Gene Therapy Market Assessment by Approach

Chapter 8. Gene Therapy Market Assessment by Route of Administration

Chapter 9. Gene Therapy Market Assessment by Region

Chapter 10. Competitive Landscape

Chapter 11. Company Profiles

List of Tables

List of Figures